Simon has over 30 years' experience in the biotech industry. This includes ten years working for Amersham International (now GE), ICI and Zeneca (now Astra Zeneca), in a variety of commercial and technical positions, and over five years with Tepnel Life Sciences plc (now Hologic Inc), an LSE listed diagnostic company where he was the Chief Executive and raised £10 million as a rights issue.
Simon then became the CEO of the embryonic start-up company, DNA Research Innovations Ltd ('DRI'), growing the company for four years which was acquired by the Invitrogen Corporation Inc for $65 million in 2004. After a period with Invitrogen Simon joined Fusion Antibodies in 2006 as the CEO and in 2011 moved to his current Chairman role. During that period he was also the Executive Chairman of Scottish based Lab 901 where he completed several rounds of funding and sold the business in 2011 to Agilent Technologies Inc. He is also currently the CEO of the VC backed diagnostic Company Biofortuna Ltd.
Dr Kerr has over 20 years' experience in the biopharmaceutical industry. He has over 15 years' experience with Fusion Antibodies, initially in a variety of technical roles followed by eight years in business development, where he was responsible for developing the Company's contract research services and seeking partners for the drug assets discovered and validated. Dr Kerr has a PhD from Queen's University Belfast in monoclonal antibody diagnostics. Previous roles were developing monoclonal antibodies at The Queens University of Belfast and Veterinary Sciences Division, Stormont laboratory and ELISA development & testing services at Campden BRI, Chipping Campden, Gloucestershire. Dr Kerr joined the Company as a Director and was appointed as CEO in 2011.
Mr Fair has eight years' experience working in the bioscience sector. A mathematics graduate, he qualified as a chartered accountant in 1992 having trained with a big four firm. He has been head of finance with Fusion Antibodies for eight years on a secondment basis and joined the Company as a Director full time on 1 August 2017, where he is responsible for all aspects of financial management including internal and external financial reporting. He has been involved in the growth of the business and previous raisings for the Company.
Mr Fair's previous experience has included senior management positions in internal audit, business and professional practice where his recent experience was in advising and supporting start up and spin out companies from Northern Ireland entrepreneurs and both local Universities.
Dr Buick has more than 19 years' experience in the biopharmaceutical industry. After graduating with a 1st Class Honours degree in Genetics, he spent four years at Randox Laboratories, discovering novel antibodies for diagnostics from synthetic libraries. He joined Fusion Antibodies in 2002, where he was responsible for overseeing the Company's contract research services and production of all reagents required for the research and development of internal drug assets. Dr Buick has a PhD from Queen's University Belfast in Immunology. He joined the Company as a Director and was appointed CTO in 2011, managing all scientific projects and Fusion Antibodies' patent portfolios. In addition, Dr Buick has, since 2015, been appointed as a legal expert witness in a number of drug patent dispute cases.
Ms Ferguson is an experienced senior director working in the pharmaceuticals industry. She is currently senior director of Q2 Solutions, a Quintiles Quest joint venture, which is a leading global clinical trials laboratory services organisation. Her previous roles include Quintiles itself and over 18 years with Randox Laboratories. Ms Ferguson joined the Company as a Director in 2016 and is a member of the Company's remuneration committee.
Member of the Remuneration Committee
Dr Mawson is a venture capital fund manager, the founder and now non-executive chairman of Clarendon Fund Managers Limited ("Clarendon"). He was an initial director of the General Partner of the Rainbow Seed Fund, now a £24 million fund, set up to commercialise technology arising from the UK public sector research laboratories, and of other fund management companies. A Master of Science of the Sloan School, MIT, Cambridge, Mass., a former consultant with McKinsey & Co, Director of Research at Wiggins Teape and Chair of Council of the University of Salford, Dr Mawson, an organic and polymer research chemist, joined the Company as a Director in 2004 as a representative of Clarendon. Clarendon is the fund manager for Nitech Growth Fund LP and Viridian Growth Fund LP which, in aggregate, will hold an interest in 9.91 per cent. of the Enlarged Share Capital on Admission. Dr Mawson is a member of the Company's audit committee.
Member of the Audit Committee
Mr Walsh is chief executive and founder of Crescent Capital and has been an active venture capital investor in the high-tech sector for the past 28 years. He has considerable experience of business strategy and governance issues, mentoring senior management plus the restructuring, growth and development of companies across many sectors. He has served on numerous boards including both as a director and chair of Andor Technology plc, an AIM listed company and Trafficmaster plc, a LSE main market listed company. A former chair of the CBI for Northern Ireland, he joined the Company as a Director in 2007 as a representative of Crescent Capital. Crescent Capital is the fund manager of Crescent Capital II LP, which will hold an interest in 15.32 per cent. of the Enlarged Share Capital on Admission. Mr Walsh is the chair of the Company's remuneration committee.
Member of the Remuneration Committee (Chair)
Mr Watts has over 25 years' experience in the pharmaceutical and biotech sectors. He qualified as a chartered accountant with Coopers & Lybrand before moving to HJ Heinz. He subsequently joined ICI in 1985, initially in the corporate headquarters before moving into the ICI Pharmaceuticals Division in 1990 (subsequently spun out of ICI into Zeneca PLC) where he held a range of positions, both financial and in general management, before being appointed Finance Director of the Zeneca Pharmaceuticals business in 1998. Following Zeneca's merger with Astra he became Group Financial Controller of AstraZeneca PLC in 2002. In 2007 Mr Watts was appointed CFO of Archimedes Pharma, a private equity backed specialty pharma company, where he served for 4 years. In February 2012 Mr Watts was appointed CFO and board member of Oxford BioMedica PLC, a leading gene and cell therapy company. He retired from Oxford BioMedica at the end of September 2017. Mr Watts is a member of the Institute of Chartered Accountants in England & Wales and the Association of Corporate Treasurers. He also was a director of the UK's BioIndustry Association from 2013 to 2017. Mr Watts chairs the Company's audit committee.
Member of the Audit Committee (Chair)